OLMA vs. IDYA, PTGX, GERN, ACAD, AMRX, ARWR, AGIO, PTCT, JANX, and VRNA
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include IDEAYA Biosciences (IDYA), Protagonist Therapeutics (PTGX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Amneal Pharmaceuticals (AMRX), Arrowhead Pharmaceuticals (ARWR), Agios Pharmaceuticals (AGIO), PTC Therapeutics (PTCT), Janux Therapeutics (JANX), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical preparations" industry.
Olema Pharmaceuticals (NASDAQ:OLMA) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, community ranking, profitability and risk.
IDEAYA Biosciences received 102 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. Likewise, 70.65% of users gave IDEAYA Biosciences an outperform vote while only 65.12% of users gave Olema Pharmaceuticals an outperform vote.
Olema Pharmaceuticals has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 19.4% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Olema Pharmaceuticals has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -483.05%. IDEAYA Biosciences' return on equity of -20.52% beat Olema Pharmaceuticals' return on equity.
Olema Pharmaceuticals has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Olema Pharmaceuticals currently has a consensus price target of $27.00, suggesting a potential upside of 112.60%. IDEAYA Biosciences has a consensus price target of $56.20, suggesting a potential upside of 50.03%. Given Olema Pharmaceuticals' higher possible upside, equities analysts clearly believe Olema Pharmaceuticals is more favorable than IDEAYA Biosciences.
In the previous week, IDEAYA Biosciences had 4 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 8 mentions for IDEAYA Biosciences and 4 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.28 beat IDEAYA Biosciences' score of 1.22 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.
Summary
IDEAYA Biosciences beats Olema Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
Free OLMA Stock Alerts